NZ756224B2 - Polypeptide variants and uses thereof - Google Patents
Polypeptide variants and uses thereof Download PDFInfo
- Publication number
- NZ756224B2 NZ756224B2 NZ756224A NZ75622418A NZ756224B2 NZ 756224 B2 NZ756224 B2 NZ 756224B2 NZ 756224 A NZ756224 A NZ 756224A NZ 75622418 A NZ75622418 A NZ 75622418A NZ 756224 B2 NZ756224 B2 NZ 756224B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- igg1
- region
- polypeptide
- substitution
- hdr5
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract 24
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 24
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 24
- 239000000427 antigen Substances 0.000 claims abstract 8
- 102000036639 antigens Human genes 0.000 claims abstract 8
- 108091007433 antigens Proteins 0.000 claims abstract 8
- 230000001270 agonistic effect Effects 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- 238000006467 substitution reaction Methods 0.000 claims 20
- 238000000034 method Methods 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 2
- -1 RANK Proteins 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- 239000004148 curcumin Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims 1
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101000679921 Homo sapiens Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 claims 1
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 claims 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 101000920026 Homo sapiens Tumor necrosis factor receptor superfamily member EDAR Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims 1
- 108010052562 RELT Proteins 0.000 claims 1
- 102000018795 RELT Human genes 0.000 claims 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims 1
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 1
- 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 claims 1
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 102100030810 Tumor necrosis factor receptor superfamily member EDAR Human genes 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Abstract
described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.
Claims (24)
1. A polypeptide comprising an Fc region of an immunoglobulin and an antigen binding region, wherein the Fc region comprises at most six substitutions, 5 including, a. an E430G substitution, and b. a K326W and a E333S substitution, wherein the positions correspond to human IgG1, according to EU numbering. 10
2. The polypeptide according to claim 1, comprising one or more further substitutions in the Fc region.
3. The polypeptide according to claim 2, wherein the further substitution is selected from K439E or S440K.
4. The polypeptide according to any one of claims 2-3, wherein the further substitution is selected from F405L or K409R.
5. The polypeptide according to any one of the preceding , wherein the 20 polypeptide is an antibody, monospecific antibody, ific antibody or multispecific antibody.
6. The ptide according to claim 5, wherein the polypeptide is a bispecific antibody comprising an Fc region comprising a first heavy chain and a first 25 antigen binding region, a second heavy chain and a second antigen g region, wherein a. said first heavy chain comprises a r substitution in a position selected form the group ting of K409, F405, T366, L368, K370, D399, Y407 30 b. said second Fc heavy chain comprises a further substitution in a position ed from the group consisting of K409, F405, T366, L368, K370, D399, Y407 c. n the further substitution in said first heavy chain and said second heavy chain are not in the same position. 20562116_1 (GHMatters) P45388NZ00
7. The polypeptide according to any one of claims 5-6, wherein a first heavy chain comprises a K409R or a F405L substitution, a second heavy chain comprises a K409R or a F405L substitution, wherein the substitution in said 5 first Fc region and said second Fc region are not the same.
8. The polypeptide according to any one of the preceding claims, wherein the Fc region is a human IgG1, IgG2, IgG3, IgG4 e or a mixed isotype. 10
9. The polypeptide ing to any one of the preceding claims, wherein the Fc region is a human IgG1 isotype.
10. The polypeptide according to any one of the preceding claims, wherein the polypeptide is a human antibody, humanized antibody or chimeric antibody.
11. The polypeptide ing to any one of the preceding claims, wherein the antigen binding region binds to a member of the tumor necrosis factor receptor super family (TNFR-SF) or G-protein Coupled Receptor (GPCR) superfamily.
12. The polypeptide according to any one of the preceding claims, wherein the antigen g region binds to a member of the F selected from the group consisting of: FAS, DR4, DR5, TNFR1, DR6, DR3, EDAR, NGFR, OX40, CD40, CD30, CD27, 4-1BB, RANK, TACI, BLySR, BCMA, RELT and GITR.
13. A method of increasing agonistic activity of a polypeptide comprising an Fc region of a human IgG and an antigen binding region, which method comprises introducing at most six substitutions, including, a. introducing an E430G tution, and 30 b. introducing a K326W and a E333S substitution, wherein the positions correspond to human IgG1, according to EU numbering.
14. A method of sing CDC activity of a polypeptide sing an Fc region of a human IgG and an antigen binding region, which method comprises 35 introducing at most six substitutions, including, 20562116_1 (GHMatters) P45388NZ00 a. ucing an E430G substitution, and b. introducing a K326W and a E333S substitution, wherein the position(s) correspond to human IgG1, according to EU numbering. 5
15. The method according to any one of claims 13-14, wherein said method comprises introducing one or more further substitutions in the Fc region.
16. The method according to any one of claims 13-15, n said method comprises introducing a further substitution in the Fc region which is K439E or 10 S440K.
17. The method according to any one of claims 13-16, wherein said method comprises introducing a further substitution is in the Fc region which is F405L or K409R. 15
18. A composition comprising at least one polypeptide as defined in any one of claims 1-17.
19. A composition sing at least two ptides as defined in any one of claims 1-17.
20. The composition according to any one of claims 18-19, wherein the composition is a pharmaceutical composition.
21. A polypeptide according to any one of claims 1-12 or a composition according 25 to any one of claims 18-20 for use as a medicament.
22. Use of a polypeptide according to any one of claims 1-12 or a composition according to any one of claims 18-20 in the manufacture of a medicament for treating of cancer, autoimmune diseases, inflammatory diseases or infectious 30 diseases.
23. A kit of parts sing a polypeptide, or composition as defined in any one of the preceding , wherein said ptide, or composition is in one or more containers such as vials. 20562116_1 (GHMatters) P45388NZ00
24. The kit of parts according to claim 23, n the polypeptide or composition as defined in any one of the preceding claims is formulated for simultaneous, separate or sequential use in therapy. 20562116_1 (GHMatters) P45388NZ00 FIGURE 1 A BxPC—3 -x- IgG1—b12 E 100 x- IgG1-b12-K326A/E333A/P396L g -o- IgG1—hDR5—O1—656T % -o- IgG1-hDR5—O1—G56T—E4306 >° 50 -I- IgG1-hDR5-O1-G56T-K326A/E333A/P396L -I:I- IgG1-hDR5—o1-G56T—K326A/E333A/P396L/E430G 0.01 1 100 10000 1000000 dy concentration (nglmL) B BXPC-3 -x— IgG1—b12 -)(- 12-K326A/E333A/P396L E 100 2 + IgG1-hDR5-05 E -o- IgG1-hDR5E43OG : 50 -I- |gG1-hDR5K326A/E333A/P396L -|:|- |gG1-hDR5K326A/E333A/P396L/E430G 0.01 1 100 10000 1000000 Antibody concentration (nglmL) BxPC-3 100 IgG1-b12 g + IgG1-hDR5-G56T+ IgG1-hDR5-05 E -o- IgG1—hDR5-G56T—E4soG + IgG1—hDR5—05—E4SOG S 50 |gG1-hDR5G56T—K326A/E333A/P396L+ °\° IgG1-hDR5K326A/E333A/P396L DR5G56T-K326A/E333A/P396L/E43OG+ -|:|- IgG1-hDR5K326A/E333A/P396L/E43OG 0.01 1 100 10000 1000000 Antibody concentration (nglmL) SUBSTITUTE SHEET (RULE 26)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201700097 | 2017-02-10 | ||
| PCT/EP2018/053464 WO2018146317A1 (en) | 2017-02-10 | 2018-02-12 | Polypeptide variants and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ756224A NZ756224A (en) | 2024-02-23 |
| NZ756224B2 true NZ756224B2 (en) | 2024-05-24 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506208A5 (en) | ||
| US11332532B2 (en) | Bispecific antibodies which bind PD-L1 and GITR | |
| HRP20240924T1 (en) | Anti-sirpalpha antibodies | |
| JP2020502046A5 (en) | ||
| HRP20211357T1 (en) | Bispecific antibodies specific for pd1 and tim3 | |
| JP2020508655A5 (en) | ||
| CN111867630A (en) | Antibodies, bispecific antibodies, ADCs and CARs targeting CLDN18.2 and their applications | |
| HRP20191174T1 (en) | Bispecific t cell activating antigen binding molecules | |
| JP2020533948A5 (en) | ||
| JP2016508153A5 (en) | ||
| TW202126694A (en) | Cd3-targeting antibody, bispecific antibody and use thereof | |
| CA2990511A1 (en) | Multispecific antigen binding proteins | |
| RU2011145428A (en) | ANTIBODIES AGAINST TNF-α AND THEIR APPLICATION | |
| JP2016529882A5 (en) | ||
| JP2018526981A5 (en) | ||
| CN111484555B (en) | Novel bispecific CD3/CD20 polypeptide complex | |
| CA3086653A1 (en) | Tumor necrosis factor (tnf) receptor superfamily (tnfrsf) receptor-activating antibody fusion proteins with fcyr-independent agonistic activity (tnfrsf receptor-activating antibody fusion proteins with fcyr-independ ent agonistic activity; traaffiaa) | |
| RU2014153440A (en) | ANTIBODIES AGAINST CD26 AND THEIR APPLICATION | |
| US20230114801A1 (en) | MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF | |
| JP2024073580A (en) | Btla antibodies | |
| TW202221042A (en) | PD-1/VEGF tetravalent bispecific antibody as well as preparation method and application thereof | |
| JP2020502233A5 (en) | ||
| US10640576B2 (en) | Cell engaging binding molecules | |
| NZ756224B2 (en) | Polypeptide variants and uses thereof | |
| NZ756224A (en) | Polypeptide variants and uses thereof |